Leukemia Research and Treatment / 2012 / Article / Tab 1

Review Article

Clinical Experience Using Vitamin D and Analogs in the Treatment of Myelodysplasia and Acute Myeloid Leukemia: A Review of the Literature

Table 1

Clinical reports of vitamin D in the treatment of patients with AML and MDS.

Vitamin D derivativeDose scheduleDuration of therapyConcurrent agentsDisorder treatedNumber treatedResponseFirst authorReference

1 alpha(OH) vitamin D34.5 to 15 microgram/day4 weeksSingle agentAML2Transient decline in marrow blastsIrino [4]
MDS1Transient decline in marrow blasts
Alfacalcidol0.25 to 10 microgram/day≥4 weeksSingle agentAML21 minor responseTakahashi [5]
MDS113 partial and 1 minor response
1 alpha(OH) vitamin D31 microgram/day>4 weeksSingle agentAML11 major responseNakayama[7]
1,25(OH)2 vitamin D32 microgram/day12 weeksSingle agentMDS188 transient, partial responsesKoeffler[6]
1 hydroxy vitamin D34 to 6 microgram/day17 monthsSingle agentMDS15Improved PFS compared to controlMotomura[8]
Calcifediol266 microgram 3 days weekUp to 2 yearsSingle agentMDS51 major responseMellibovsky[9]
Calcitriol0.25 to 0.75 microgram/dayUp to 2 yearsSingle agentMDS1410 responders, 2 majorMellibovsky[9]
Alfacalcidiol6 microgram/day6 monthsSingle agentMDS131 transient responseYoshida[11]
Doxercalciferol12.5 microgram/day12 weeksSingle agentMDS15No formal responsePetrich[12]
1,25(OH)2 vitamin D30.75 microgram/day12 weeksPrednisone + 13 cis-Retinoic AcidMDS11 major responseBlazsek[13]
1,25(OH)2 vitamin D313 microgram/day16 weeksValproic acidMDS193 major responseSiitonen[14]
1 alpha(OH) vitamin D31 microgram/dayVariableCytarabine ± IFN ± RetinoidsAML155 responses (including stable disease) Hellström[15]
1 alpha(OH) vitamin D31 microgram/dayVariableCytarabine ± IFN ± RetinoidsMDS4722 responses (including stable disease) Hellström[15]
1 alpha(OH) vitamin D31 microgram/dayVariableCytarabine ± 13 cis-Retinoic AcidMDS6913 responses Hellström[16]
1 alpha(OH) vitamin D31 microgram/day VariableCytarabine ± 13 cis-Retinoic AcidAML155 responses Hellström[16]
1,25(OH)2 vitamin D30.75 microgram/dayVariableCytarabine + 13 cis-Retinoic AcidMDS4422 responsesDe Rosa[17]
1,25(OH)2 vitamin D31 to 1.5 microgram/dayUntil progression13 cis-Retinoic Acid + 6TGMDS3119 responses (patients with >5% blasts)Ferrero[18]
Dihydroxy-vitamin D31 microgram/dayUntil progressionCytarabine + 13 cis-Retinoic AcidAML2615 responses among all treatedFerrero[19]
Dihydroxy-vitamin D31 microgram/dayUntil progressionCytarabine + 13 cis-Retinoic AcidMDS415 responses among all treatedFerrero[19]
1,25(OH)2 vitamin D30.5 microgram/dayUntil progressionCytarabineAML2923 Slapak[20]
1,25 di(OH) vitamin D31 microgram/day>6 months13-cis retinoic acid, 6TG, EpoMDS6338Ferrero[21]
1-alpha hydroxy-vitamin
0.75 microgram/day16 weeksVitamin KMDS206Akiyama[22]

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.